Adipose Derived Stromal Vascular Fraction Cells

Drug Overview

Afatinib dimaleate is a highly specialized cancer medication known as a “Targeted Therapy” or “Smart Drug.” Unlike traditional chemotherapy, which attacks all fast-growing cells in the body, targeted therapies are designed to find and attack specific mutant proteins on cancer cells. This makes the treatment more precise.

Adipose Derived Stromal Vascular Fraction Cells is primarily used to treat certain types of lung cancer. It is prescribed for patients whose lung cancer has spread to other parts of the body and carries specific genetic changes (mutations).

• Generic Name: Afatinib dimaleate
• US Brand Names: Gilotrif (often marketed as Giotrif in European and other international markets)
• Drug Class: Tyrosine Kinase Inhibitor (TKI); EGFR / ErbB Family Blocker
• Route of Administration: Oral (Tablet)
• FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

Afatinib dimaleate works by blocking the signals that tell cancer cells to grow and multiply.

To understand how it works at the molecular level, imagine the outside of a cancer cell covered in tiny antennas. These antennas are called receptors. In some lung cancers, a specific family of these antennas—called the ErbB family (which includes the Epidermal Growth Factor Receptor, or EGFR)—is broken. Because of a genetic mutation, these antennas are permanently turned “on,” constantly sending a signal to the cell’s core telling it to grow, divide, and spread.

Afatinib dimaleate is a small molecule that enters the body and specifically targets these broken antennas. It binds to the inner parts of the EGFR, HER2, and HER4 receptors. Unlike older drugs that might briefly stick to these receptors and fall off, afatinib binds to them irreversibly (permanently). By permanently plugging up these antennas, the drug shuts down the signaling pathways (known as the PI3K/Akt and MAPK/ERK pathways). Without these signals, the cancer cells stop growing and eventually die off.

FDA Approved Clinical Indications

Afatinib dimaleate is officially approved by the FDA and international health agencies for specific uses:

Oncological Uses

• First-line treatment for Metastatic Non-Small Cell Lung Cancer (NSCLC): Specifically for patients whose tumors have abnormal EGFR genes (such as exon 19 deletions or exon 21 L858R mutations).
• Treatment of Metastatic Squamous NSCLC: For patients whose cancer has worsened after trying standard platinum-based chemotherapy.

Non-Oncological Uses

• None. This medication is strictly used for cancer treatment.

Dosage and Administration Protocols

Afatinib dimaleate is taken as a pill at home. It is very important that it is taken on an empty stomach to ensure the body absorbs the right amount of the drug.

Dose Adjustments

• Renal Insufficiency (Kidney Issues): For patients with severe kidney problems, the starting dose is usually reduced to 30 mg once daily.
• Hepatic Insufficiency (Liver Issues): No starting dose adjustment is generally needed for mild to moderate liver issues, but doctors will monitor liver blood tests closely. If severe liver problems develop during treatment, the drug may be paused or stopped.
• Side Effect Adjustments: If a patient experiences severe diarrhea or skin rashes, the doctor may lower the dose in 10 mg steps (down to 30 mg or 20 mg).

Clinical Efficacy and Research Results

Clinical trials (such as the LUX-Lung studies) and recent real-world data from 2020 to 2025 have proven that afatinib dimaleate is highly effective for patients with specific EGFR mutations.

• Disease Progression: In large studies, patients taking afatinib dimaleate as their first treatment saw a significant delay in their cancer growing compared to standard chemotherapy. On average, the drug can halt tumor growth (Progression-Free Survival) for over 11 to 13 months, and even longer in certain patient groups.
• Survival Rates: Research shows that patients with the most common EGFR mutation (exon 19 deletion) who take afatinib live significantly longer overall compared to those receiving traditional chemotherapy.
• Tumor Shrinkage: A large majority of patients (often over 60-70% depending on the exact mutation) experience noticeable shrinkage of their lung tumors while on this targeted therapy.

Safety Profile and Side Effects

Because this drug targets the EGFR protein, which is also found in healthy skin and the lining of the gut, it can cause specific side effects in those areas.

No Black Box Warning

Currently, there is no FDA Black Box Warning for afatinib dimaleate, but it does carry strong warnings regarding severe diarrhea and skin reactions.

Common Side Effects (Occur in >10% of patients)

• Diarrhea: This is the most common side effect and can happen quickly.
• Skin Rash / Acne-like Breakouts: The skin may become red, dry, and itchy.
• Stomatitis: Painful sores or redness inside the mouth and lips.
• Paronychia: Inflammation or infection around the fingernails or toenails.
• Decreased Appetite and Weight Loss.

Serious Adverse Events (Occur rarely)

• Severe Dehydration and Kidney Failure: Usually caused by unmanaged, severe diarrhea.
• Interstitial Lung Disease (ILD): A severe and potentially life-threatening inflammation and scarring of the lungs.
• Hepatotoxicity: Liver damage.
• Keratitis: Inflammation of the eye that can cause pain and vision changes.

Side Effect Management Strategies

• For Diarrhea: Doctors will prescribe an anti-diarrhea medicine (like loperamide) to keep at home. Patients must start taking it at the very first sign of loose stools and drink plenty of water.
• For Skin Rashes: Use alcohol-free, thick moisturizing creams daily. Avoid long, hot showers.
• For Nail Care: Keep hands clean and dry. Wear gloves when doing dishes or housework to protect the nails.

Research Areas

Afatinib dimaleate is actively being studied to see how it can be used even more effectively. A major challenge with targeted therapies is that cancer cells are “smart” and can eventually mutate again to hide from the drug (a process called acquired resistance). Current research focuses on combining afatinib with other targeted drugs, or with newer immunotherapy agents, to overcome this resistance and keep the cancer cells from finding a new way to grow. There is currently no standard application linking this drug directly to stem cell therapies or regenerative medicine.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

• Molecular Profiling (Biopsy Test): A doctor must test the tumor tissue to confirm it has the specific EGFR mutations that afatinib is designed to attack.
• Liver and Kidney Function Tests: Blood work to ensure the organs can safely process the medicine.
• Pregnancy Test: For women of childbearing age, as this drug can harm an unborn baby.

Precautions During Treatment

• Sun Sensitivity: This medication makes the skin highly sensitive to sunlight. Patients can get severe sunburns very quickly.

Do’s and Don’ts

• DO take the pill at the same time every day to keep a steady amount of medicine in your body.
• DO wear broad-spectrum sunscreen (SPF 30 or higher), a hat, and protective clothing when going outside.
• DO tell your care team immediately if you develop a new, unexplained cough, fever, or shortness of breath (possible signs of lung inflammation).
• DON’T take the pill with food. Remember the rule: at least 1 hour before eating, or at least 2 hours after eating.
• DON’T interact with anyone who has a severe infection, as your body is fighting a serious illness.
• DON’T become pregnant or breastfeed while taking this medication and for at least two weeks after the last dose.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease or health condition. Always consult with a qualified healthcare professional or your treating oncologist regarding specific medical concerns, treatment options, or before starting, stopping, or altering any medication regimen. Every patient’s medical situation is unique, and therapies should be customized by a licensed physician.